Alan E. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alan E. Jones has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Michael Alexander Puskarich
Department of Emergency Medicine, University of Minnesota, Minneapolis, MN 55364, USA
5 shared publications - Kathleen A. Stringer
Department of Clinical Pharmacy, College of Pharmacy University of Michigan Ann Arbor Michigan USA
4 shared publications - Alla Karnovsky
Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA
3 shared publications - Theodore S. Jennaro
Department of Clinical Pharmacy, College of Pharmacy University of Michigan Ann Arbor Michigan USA
3 shared publications - Charles R. Evans
University of Michigan
2 shared publications - Christopher E. Gillies
Regeneron Genetics Center
2 shared publications
Latest Publications
- Open Access
- 11 October 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (12) , 1240-1250
Kidney function as a key driver of the pharmacokinetic response to high‐dose L‐carnitine in septic shock
Study Objective: Levocarnitine (L‐carnitine) has shown promise as a metabolic‐therapeutic for septic shock, where mortality approaches 40%. However, high‐dose (≥ 6 grams) intravenous supplementation results in a broad range of serum concentrations. We sought to describe the population pharmacokinetics (PK) of high‐dose L‐carnitine, test various estimates of kidney function, and assess the correlation of PK parameters with pre‐treatment metabolites in describing drug response for patients with septic shock. Design: Population PK analysis was done with baseline normalized concentrations using nonlinear mixed effect models in the modeling platform Monolix. Various estimates of kidney function, patient demographics, dose received, and organ dysfunction were tested as population covariates. Data Source: We leveraged serum samples and metabolomics data from a phase II trial of L‐carnitine in vasopressor‐dependent septic shock. Serum was collected at baseline (T0); end‐of‐infusion (T12); and 24, 48, and 72 h after treatment initiation. Patients and Intervention: Patients were adaptively randomized to receive intravenous L‐carnitine (6 grams, 12 grams, or 18 grams) or placebo. Measurements and Main Results: The final dataset included 542 serum samples from 130 patients randomized to L‐carnitine. A two‐compartment model with linear elimination and a fixed volume of distribution (17.1 liters) best described the data and served as a base structural model. Kidney function estimates as a covariate on the elimination rate constant (k) reliably improved model fit. Estimated glomerular filtration rate (eGFR), based on the 2021 Chronic Kidney Disease Epidemiology collaboration (CKD‐EPI) equation with creatinine and cystatin C, outperformed creatinine clearance (Cockcroft‐Gault) and older CKD‐EPI equations that use an adjustment for self‐identified race. Conclusions: High‐dose L‐carnitine supplementation is well‐described by a two‐compartment population PK model in patients with septic shock. Kidney function estimates that leverage cystatin C provided superior model fit. Future investigations into high‐dose L‐carnitine supplementation should consider baseline metabolic status and dose adjustments based on renal function over a fixed or weight‐based dosing paradigm.
- 11 October 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (12) , 1240-1250
Open AccessKidney function as a key driver of the pharmacokinetic response to high‐dose L‐carnitine in septic shock
Study Objective: Levocarnitine (L‐carnitine) has shown promise as a metabolic‐therapeutic for septic shock, where mortality approaches 40%. However, high‐dose (≥ 6 grams) intravenous supplementation results in a broad range of serum concentrations. We sought to describe the population pharmacokinetics (PK) of high‐dose L‐carnitine, test various estimates of kidney function, and assess the correlation of PK parameters with pre‐treatment metabolites in describing drug response for patients with septic shock. Design: Population PK analysis was done with baseline normalized concentrations using nonlinear mixed effect models in the modeling platform Monolix. Various estimates of kidney function, patient demographics, dose received, and organ dysfunction were tested as population covariates. Data Source: We leveraged serum samples and metabolomics data from a phase II trial of L‐carnitine in vasopressor‐dependent septic shock. Serum was collected at baseline (T0); end‐of‐infusion (T12); and 24, 48, and 72 h after treatment initiation. Patients and Intervention: Patients were adaptively randomized to receive intravenous L‐carnitine (6 grams, 12 grams, or 18 grams) or placebo. Measurements and Main Results: The final dataset included 542 serum samples from 130 patients randomized to L‐carnitine. A two‐compartment model with linear elimination and a fixed volume of distribution (17.1 liters) best described the data and served as a base structural model. Kidney function estimates as a covariate on the elimination rate constant (k) reliably improved model fit. Estimated glomerular filtration rate (eGFR), based on the 2021 Chronic Kidney Disease Epidemiology collaboration (CKD‐EPI) equation with creatinine and cystatin C, outperformed creatinine clearance (Cockcroft‐Gault) and older CKD‐EPI equations that use an adjustment for self‐identified race. Conclusions: High‐dose L‐carnitine supplementation is well‐described by a two‐compartment population PK model in patients with septic shock. Kidney function estimates that leverage cystatin C provided superior model fit. Future investigations into high‐dose L‐carnitine supplementation should consider baseline metabolic status and dose adjustments based on renal function over a fixed or weight‐based dosing paradigm.
- Open Access
- 27 December 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 128, 223-229
Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
- 27 December 2022
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 128, 223-229
Open AccessLopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
- Open Access
Pharmacometabolomics Identifies Candidate Predictor Metabolites of an L-carnitine Treatment Mortality Benefit in Septic Shock
Background: Sepsis-induced metabolic dysfunction contributes to organ failure and death. L-carnitine has shown promise for septic shock, but a recent study demonstrated a non-significant reduction in mortality. Methods: A pharmacometabolomics study of patients (n=250) in a Phase II trial of L-carnitine to identify metabolic profiles predictive of a 90-day mortality benefit from L-carnitine. The independent predictive value of each pre-treatment metabolite concentration, adjusted for L-carnitine dose, on 90-day mortality was determined by logistic regression. A grid-search analysis maximizing the Z-statistic from a binomial proportion test identified specific metabolite threshold levels that discriminated L-carnitine responsive patients. Threshold concentrations were further assessed by hazard-ratio and Kaplan-Meier estimate. Findings: Accounting for L-carnitine treatment and dose, 11 1 H-NMR metabolites and 12 acylcarnitines were independent predictors of 90-day mortality. Based on the grid-search analysis numerous acylcarnitines and valine were identified as candidate metabolites of drug response. Acetylcarnitine emerged as highly viable for the prediction of an L-carnitine mortality benefit due to its abundance and biological relevance. Using its most statistically significant threshold concentration, patients with acetylcarnitine ≥35µM were less likely to die at 90 days if treated with L-carnitine (18 g) versus placebo (p=0.01 by log rank test). Interpretation: Metabolomics identified independent predictors of 90-day sepsis mortality. Our proof-of-concept approach shows how pharmacometabolomics may be useful for tackling the heterogeneity of sepsis and informing clinical trial design. Also, metabolomics can help understand mechanisms of sepsis heterogeneity and variable drug response, since sepsis induces alterations in numerous metabolite concentrations.
Open AccessPharmacometabolomics Identifies Candidate Predictor Metabolites of an L-carnitine Treatment Mortality Benefit in Septic Shock
Background: Sepsis-induced metabolic dysfunction contributes to organ failure and death. L-carnitine has shown promise for septic shock, but a recent study demonstrated a non-significant reduction in mortality. Methods: A pharmacometabolomics study of patients (n=250) in a Phase II trial of L-carnitine to identify metabolic profiles predictive of a 90-day mortality benefit from L-carnitine. The independent predictive value of each pre-treatment metabolite concentration, adjusted for L-carnitine dose, on 90-day mortality was determined by logistic regression. A grid-search analysis maximizing the Z-statistic from a binomial proportion test identified specific metabolite threshold levels that discriminated L-carnitine responsive patients. Threshold concentrations were further assessed by hazard-ratio and Kaplan-Meier estimate. Findings: Accounting for L-carnitine treatment and dose, 11 1 H-NMR metabolites and 12 acylcarnitines were independent predictors of 90-day mortality. Based on the grid-search analysis numerous acylcarnitines and valine were identified as candidate metabolites of drug response. Acetylcarnitine emerged as highly viable for the prediction of an L-carnitine mortality benefit due to its abundance and biological relevance. Using its most statistically significant threshold concentration, patients with acetylcarnitine ≥35µM were less likely to die at 90 days if treated with L-carnitine (18 g) versus placebo (p=0.01 by log rank test). Interpretation: Metabolomics identified independent predictors of 90-day sepsis mortality. Our proof-of-concept approach shows how pharmacometabolomics may be useful for tackling the heterogeneity of sepsis and informing clinical trial design. Also, metabolomics can help understand mechanisms of sepsis heterogeneity and variable drug response, since sepsis induces alterations in numerous metabolite concentrations.
- Open Access
- 1 April 2018
- Published by Wolters Kluwer Health in Shock
- Vol. 49 (4) , 412-419
Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation
Introduction: Sepsis-induced metabolic disturbances include hyperlactatemia, disruption of glycolysis, protein catabolism, and altered fatty acid metabolism. It may also lower serum l-carnitine that supports the use of l-carnitine supplementation as a treatment to ameliorate several of these metabolic consequences. Methods: To further understand the association between l-carnitine-induced changes in serum acylcarnitines, fatty acid metabolism and survival, serum samples from (T0), 12 hfollowing completion (T24) of l-carnitine (n = 16) or placebo (n = 15) administration, and 48 h (T48) after enrollment from patients with septic shock enrolled in a randomized control trial were assayed for acylcarnitines, free fatty acids, and insulin. Data were analyzed comparing 1-year survivors and nonsurvivors within treatment groups. Results: Mortality was 8 of 16 (50%) and 12 of 15 (80%) at 1 year for l-carnitine and placebo-treated patients, respectively. Free carnitine, C2, C3, and C8 acylcarnitines were higher among nonsurvivors at enrollment. l-Carnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors. Several fatty acids followed a similar, though less consistent pattern. Glucose, lactate, and insulin levels did not differ based on survival or treatment arm. Conclusions: In human patients with septic shock, l-Carnitine supplementation increases a broad range of acylcarnitine concentrations that persist after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome. Nonsurvivors demonstrate a distinct metabolic response to l-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment.
- 1 April 2018
- Published by Wolters Kluwer Health in Shock
- Vol. 49 (4) , 412-419
Open AccessSeptic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation
Introduction: Sepsis-induced metabolic disturbances include hyperlactatemia, disruption of glycolysis, protein catabolism, and altered fatty acid metabolism. It may also lower serum l-carnitine that supports the use of l-carnitine supplementation as a treatment to ameliorate several of these metabolic consequences. Methods: To further understand the association between l-carnitine-induced changes in serum acylcarnitines, fatty acid metabolism and survival, serum samples from (T0), 12 hfollowing completion (T24) of l-carnitine (n = 16) or placebo (n = 15) administration, and 48 h (T48) after enrollment from patients with septic shock enrolled in a randomized control trial were assayed for acylcarnitines, free fatty acids, and insulin. Data were analyzed comparing 1-year survivors and nonsurvivors within treatment groups. Results: Mortality was 8 of 16 (50%) and 12 of 15 (80%) at 1 year for l-carnitine and placebo-treated patients, respectively. Free carnitine, C2, C3, and C8 acylcarnitines were higher among nonsurvivors at enrollment. l-Carnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors. Several fatty acids followed a similar, though less consistent pattern. Glucose, lactate, and insulin levels did not differ based on survival or treatment arm. Conclusions: In human patients with septic shock, l-Carnitine supplementation increases a broad range of acylcarnitine concentrations that persist after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome. Nonsurvivors demonstrate a distinct metabolic response to l-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment.
- 21 March 2017
- Published by Cambridge University Press (CUP)
- p. 139-147
Coordinating Emergency Care through Telemedicine
- 21 March 2017
- Published by Cambridge University Press (CUP)
- p. 139-147
Coordinating Emergency Care through Telemedicine
- Open Access
- 1 October 2016
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 68 (4) , S147
385 Plasma Syndecan-1 Levels Identify a Cohort of Patients With Severe Sepsis at a High Risk of Intubation Following Large Volume Intravenous Fluid Resuscitation
- 1 October 2016
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 68 (4) , S147
Open Access385 Plasma Syndecan-1 Levels Identify a Cohort of Patients With Severe Sepsis at a High Risk of Intubation Following Large Volume Intravenous Fluid Resuscitation
- 1 December 2014
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 42, A1601
1000
- 1 November 2013
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 62 (5) , 534-535
Is the Addition of Vasopressin to Norepinephrine Beneficial for the Treatment of Septic Shock?
- 1 November 2013
- Published by Elsevier in Annals of Emergency Medicine
- Vol. 62 (5) , 534-535
Is the Addition of Vasopressin to Norepinephrine Beneficial for the Treatment of Septic Shock?